Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).

ESMO open·2026

Same author

Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.

ESMO open·2026

Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026

Same author

The Impact of Dual Cannabis and Tobacco Smoking in Young Patients With Lung Cancer: Results From the Prospective "Environment and Lung Cancer" Study.

Chest·2025

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

[ERCC1 and lung cancer].

D Planchard¹, K-A Olaussen, J-C Soria

¹Unité Inserm U981, institut Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France.

Revue Des Maladies Respiratoires

|April 21, 2010

Summary

ERCC1 (excision repair cross-complementation group 1) status predicts non-small cell lung cancer (NSCLC) patient response to cisplatin chemotherapy. ERCC1-negative tumors benefit more from adjuvant chemotherapy, while ERCC1-positive tumors indicate a better prognosis.

Area of Science:

Molecular biology
Oncology
Genetics

Context:

Cisplatin is a cornerstone chemotherapy agent for non-small cell lung cancer (NSCLC).
ERCC1 (excision repair cross-complementation group 1) is a key DNA repair protein.
ERCC1's role in repairing cisplatin-induced DNA damage is well-established.

Purpose:

To investigate the predictive value of ERCC1 expression in NSCLC patients undergoing cisplatin-based chemotherapy.
To evaluate ERCC1 as a biomarker for treatment response and prognosis in NSCLC.

Summary:

ERCC1 expression levels (protein or mRNA) can be measured using immunohistochemistry or gene expression analysis.
Patients with ERCC1-negative NSCLC tumors showed a greater benefit from adjuvant cisplatin chemotherapy.

Related Experiment Videos

Last Updated: Jun 13, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Conversely, ERCC1-positive NSCLC tumors are associated with a better intrinsic prognosis.

Impact:

ERCC1 is a promising biomarker for predicting benefit from cisplatin-based chemotherapy in NSCLC.
Modulating ERCC1 activity could potentially sensitize NSCLC tumors to cisplatin.
Further prospective validation studies are ongoing for clinical implementation in both resected and metastatic NSCLC.